FindTrial
Sign In

observation study of segment citrate anticoagulation, argatroban and heparin-free hemodialysis in patients at high risk of bleeding

observation study of segment citrate anticoagulation, argatroban and heparin-free hemodialysis in patients at high risk of bleeding

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800014721
Enrollment
Unknown
Registered
2018-01-31
Start date
2018-02-10
Completion date
Unknown
Last updated
2018-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

the maintenance hemodialysis patients with high risk of bleeding

Interventions

without hepairn group:normal saline
argatroban group:argatroban
citrate anticoagulation group:citrate anticoagulation

Sponsors

The Affiliated Wuxi 2nd People's Hospital of Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: patients at high risk of bleeding with hemodalysis in our hosiptial from 2018.1 to 2019.1

Exclusion criteria

Exclusion criteria: liver failure, shock and hyoxemia

Design outcomes

Primary

MeasureTime frame
KT/V;the coagulation situation in dialyzers and tubes;clotting mechanism;bleeding events;—

Secondary

MeasureTime frame
blood gas analysis;vital signs;—

Countries

China

Contacts

Public ContactFeng Yan

The Affiliated Wuxi 2nd People's Hospital of Nanjing Medical University

Yf2250@126.com+86 18795968468

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026